Agoracom Blog Home

Posts Tagged ‘small cap’

Innocan Pharma’s $INNO.ca Clinical Study in the US Indicates that More than 90% of Participants Experienced Pain Reduction After Using Innocan’s Relief &Go OTC Pain Relief Spray $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:11 PM on Monday, October 19th, 2020
Innocan-Blog
  • Study indicates that more than 90 % of participants experienced reduction in pain after using Innocan’s Relief & Go OTC Pain Relief Spray
  • The clinical study was conducted on 18 participants: 10 participants with chronic pain and 8 participants with pain associated with other circumstances
  • Most participants described their pain before using the spray as throbbing and uncomfortable and a few described their pain as distressing

Herzliya, Israel and Calgary, Alberta–(October 19, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today a Clinical Study, conducted by Dr. Josef Geldwert and the Center for Podiatric Care & Sports Medicine in New York. The study indicates that more than 90 % of participants experienced reduction in pain after using Innocan’s Relief & Go OTC Pain Relief Spray. The clinical study was conducted on 18 participants: 10 participants with chronic pain and 8 participants with pain associated with other circumstances. Most participants described their pain before using the spray as throbbing and uncomfortable and a few described their pain as distressing. The location of the pain varied from the upper extremities of the back to the lower extremities and feet.

After 20 minutes 83% of participants noticed immediate improvement in pain.
After 60
 minutes 95% of participants noted relief from pain.
After 24 hours almost 90%
 noted relief from pain.

15 of the 18 participants would recommend the Relief and GO pain spray.


Relief and GO Pain Spray

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/66309_f493f3f5d4ab1931_002full.jpg

The Center for Podiatric Care & Sports Medicine in New York specializes in treating chronic problems resulting from sports injuries and active lifestyles.

Dr. Josef Geldwert has over 40 years of experience in foot surgery, biomechanics, and sports injuries. In addition, he has been a medical authority to numerous professional sports teams.

In addition, Dr. Geldwert serves as advisor on Innocan Pharma’s Scientific Advisory committee.

Innocan Pharma’s Relief & Go Pain Relief Spray is a patent pending Over-The-Counter solution designed to relieve pain by combing three different mechanisms in one product: Menthol and Methyl salicylate with CBD and Magnesium.

Dr. Josef Geldwert stated, “I have been following up with patients who I have been seeing for foot and ankle related problems that have been using Relief and Go Pain Relief Spray, and their responses have been positive. I am impressed by how well patients have been doing with a non-prescriptive OTC pain relief spray.”

“We are thrilled that our clinical test yielded such promising results,” says Ms. Iris Bincovich, Chief Executive Officer of Innocan, “Our unique approach and deep experience is exemplified in these impressive results that I’m certain are only the beginning.”

About Innocan

Innocan Israel, a wholly owned subsidiary of the Company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable

PyroGenesis $PYR.ca Announces Upsize of its Previously Announced Bought-Deal Short Form Prospectus Offering of Units to a Total of $12 Million, Including Full Exercise of the Over-Allotment Option $RTN $NOC $UTX $DDD.ca

Posted by AGORACOM-JC at 10:37 AM on Friday, October 16th, 2020
  • Entered into a revised agreement with Mackie Research Capital Corporation to increase the size of the previously announced bought-deal short-form prospectus offering of units of the Company at a price of $3.60 per Unit to 2,917,000 for gross proceeds of $10,501,200
  • Concurrently announces the full exercise of the over-allotment option of 437,550 Units for additional gross proceeds of $1,575,180.
  • The aggregate gross proceeds to the Company from the sale of Units, including the full exercise of the over-allotment option, is $12,076,380

MONTREAL, Oct. 16, 2020 – PyroGenesis Canada Inc. (“PyroGenesis” or the “Company”) (TSXV:PYR) (OTCQB:PYRNF) (FRA:8PY) is pleased to announce that it has entered into a revised agreement with Mackie Research Capital Corporation (as the sole underwriter and sole bookrunner, the “Underwriter”), to increase the size of the previously announced bought-deal short-form prospectus offering of units of the Company (the “Units”) at a price of $3.60 per Unit to 2,917,000 for gross proceeds of $10,501,200 and concurrently announces the full exercise of the over-allotment option of 437,550 Units for additional gross proceeds of $1,575,180. The aggregate gross proceeds to the Company from the sale of Units, including the full exercise of the over-allotment option, is $12,076,380 (the “Offering”).

Each Unit shall be comprised of one common share of the Company (a “Common Share“) and one-half of one Common Share purchase warrant of the Company (each whole warrant, a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one additional Common Share at an exercise price of $4.50 at any time up to 24 months from Closing (as defined herein).

Provided that if, at any time prior to the expiry date of the Warrants, the volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the “Exchange”), or other principal exchange on which the Common Shares are listed, is greater than $6.75 for 20 consecutive trading days, the Company may, within 15 days of the occurrence of such event, deliver a notice to the holders of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice (the “Accelerated Exercise Period”). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.

The net proceeds from the Offering will be used for working capital and general corporate purposes.

The Units will be offered by way of a short form prospectus to be filed in those provinces of Canada as the Underwriter may designate pursuant to National Instrument 44-101 – Short Form Prospectus Distributions and may be offered in the United States on a private placement basis pursuant to an appropriate exemption from the registration requirements under applicable U.S. law.

The Closing of the Offering is expected to occur on or about October 30, 2020 (the (“Closing”) and is subject to the Company receiving all necessary regulatory approvals, including the approval of the Exchange.

About Pyrogenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

For Further Information, Please Contact:

Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,

Phone: (514) 937-0002, E-mail: [email protected]

RELATED LINK: http://www.pyrogenesis.com/

Cautionary Note Regarding Forward Looking Information:

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

Augmented Reality’s #AR Applications And Future In Business – SPONSOR: Imagine AR $IP.ca $IPNFF $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 9:35 AM on Friday, October 16th, 2020

SPONSOR: Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) is an Augmented Reality platform that allows businesses to easily launch AR campaigns. Clients Include: NBA Sacramento Kings, Mall of America, AT&T Shape and The Basketball Hall of Fame. ImagineAR and NFL Alumni Academy recently signed a 5 year partnership agreement. In addition, the company signed a two-year agreement with Valencia C.F. of La Liga to provide interactive Augmented Reality experiences for almost 7 million fans around the world. Learn More.

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Augmented Reality’s Applications And Future In Business

  • AR market alone is estimated to grow to $61.39 billion by 2023
  • To meet the growing demand, an ecosystem of AR devices powered by platforms being developed by IT giants is evolving rapidly
  • AR has now arrived in the industrial mainstream

Gautam Goswami Forbes Councils Member

Early versions of extended reality devices, or XR, began appearing years ago, as consumer gaming platforms. Nintendo’s pioneering 1995 Virtual Boy console was touted as “a 3-D game for a 3-D world!” But within months, it had become a marketplace flop.

Even so, the development of the two primary XR formats, virtual reality (VR) and augmented reality (AR), never stopped. Today, 25 years after Virtual Boy, forward-looking investors have been encouraged by a strong interest in XR systems from major tech companies. Both technologies enhance the user’s visual world. But they work in different ways, and over time, the two have evolved in different directions.

With VR, the user wears a pair of goggles that display a world in which every image has either been captured on film, synthesized electronically or merged through a combination of the two. 

With AR, the images are seen using a smartphone, a tablet or special glasses. The basis of this imagery is whatever is seen by the device’s camera, with real-time overlays of computer-generated 2D, 3D and text, simulated by computer or from the remote input of another user.

One of AR’s biggest splashes happened in 2016 when Nintendo released its Pokémon Go game. It brought the magic of AR to millions around the world for the first time and helped to legitimize its use in everyday life.

Leading global corporations, including Facebook, Google, Microsoft, Sony and Samsung, are already spending hundreds of millions of dollars on the development of both AR and VR. And the AR market alone is estimated to grow to $61.39 billion by 2023.

AR’s Practical Uses In Business Today 

AR applications seem to have evolved toward more practical business applications. For example, sportswear company Lacoste has an app that allows in-store shoppers to place their foot on a designated spot to view the shoes of their choice through their smartphone, showing product details, custom sizes and how it would look on the customer. And The New York Times used an AR app in connection with its 2018 Winter Olympics coverage to allow users to bring up athletes on the screen to explain their maneuvers just as those moves were taking place.

The latest Apple iPad and Google smartphones feature enhanced AR capabilities through advances in camera technologies. And applications from companies like Warby Parker (virtual eyeglasses try-on) and IKEA (virtual furniture placement in rooms), among others, are providing enhanced AR experiences without the need for specialized hardware. 

Further, until this year, the primary method for installing or repairing a complex piece of industrial machinery was to have an expert from the machine’s original equipment manufacturer (OEM) jump on a plane and fly out to service the company’s equipment on site. Then Covid-19 hit. One of its many consequences has been a sharp reduction in business travel. But the need to service sophisticated industrial equipment in factories, airline hangars, power plants, offshore oil platforms and other continuously operated facilities hasn’t declined.

At TeamViewer, one of our solutions is remote virtual assistance and visual instructions enabled by AR. For many of the business leaders I’ve spoken with recently, AR has been the key solution for their equipment repairs during this time. 

The way this type of AI solution works is a technician at the facility, using only a smartphone with an AR app, can point their camera toward the machine while an expert views that image on their own device. Using a variety of techniques to highlight critical features of that image, including drop arrows, finger-drawn circles, graphics, colors, text, Internet of Things (IoT) data and more, the expert can talk the on-site technician through diagnostics, repair procedures, replacement part identification and any other support needed to enable on-site personnel and enhance the facility’s workflow. Sessions can be easily recorded and retained for step-by-step training and instruction for real-time use in similar situations at other locations.

The Future Of AR In Workforce Training

The way I see it, the AR capability is particularly important now due to the industrial world’s shifting workforce demographics. For one thing, many technically skilled workers are aging out of the workforce. As they leave, the decades of experience and expertise they had accumulated leave with them. Those who replace them, including millennials, contractors and workers retrained and recruited from other industries, simply don’t have the experience of older workers and, in many cases, can be more difficult to retain.

Despite the much-touted journeys of digital transformation being undertaken by many companies, when it comes to their operations on the factory floor, manual manufacturing techniques often still rely on legacy tools and methods to capture information and share knowledge. A 2018 white paper by ARC Advisory Group noted that most workers on the factory floor remain disconnected from the rich informational ecosystem that the rest of the organization has come to rely on. By adopting AR solutions, the paper states, manufacturing organizations can empower their factory workers in training and guidance applications.

By integrating AR, you can lead your team toward the democratization of knowledge and solve a key roadblock shared by logistics, manufacturing and field service: the experience gap. Based on my perspective in the industry, AR has moved well beyond the proof-of-concept stage, particularly where it involves guided manual assembly and maintenance. Using it, we can equip our young employees and newcomers to perform complex tasks, leading to reduced costs, higher quality and increased on-time delivery. 

To meet the growing demand, an ecosystem of AR devices powered by platforms being developed by IT giants is evolving rapidly. AR has now arrived in the industrial mainstream. In the next few years, I believe we will see it grow exponentially, transforming business processes and mitigating the knowledge gap resulting from today’s retiring generation of experienced workers.

Source: https://www.forbes.com/sites/forbescommunicationscouncil/2020/10/15/augmented-realitys-applications-and-future-in-business/#35c81bf82b3c

PyroGenesis $PYR.ca Announces $5 Million Bought-Deal Short Form Prospectus Offering of Units $RTN $NOC $UTX $DDD.ca

Posted by AGORACOM-JC at 5:37 PM on Thursday, October 15th, 2020
  • Entered into an agreement with Mackie Research Capital Corporation (as the sole underwriter and sole bookrunner, pursuant to which the Underwriter have agreed to purchase, on a bought-deal basis, 1,600,000 units of the Company for gross proceeds to the Company of $5,760,000 at a price of $3.60 per Unit.
  • Each Unit shall be comprised of one common share of the Company and one-half of one Common Share purchase warrant of the Company
  • Each Warrant shall entitle the holder thereof to purchase one additional Common Share at an exercise price of $4.50 at any time up to 24 months from Closing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

MONTREAL, Oct. 15, 2020 — PyroGenesis Canada Inc. (“PyroGenesis” or the “Company”) (TSXV:PYR) (OTCQB:PYRNF) (FRA:8PY) is pleased to announce that is has entered into an agreement with Mackie Research Capital Corporation (as the sole underwriter and sole bookrunner, the “Underwriter”), pursuant to which the Underwriter have agreed to purchase, on a bought-deal basis, 1,600,000 units of the Company (the “Units”) for gross proceeds to the Company of $5,760,000 (the “Offering“) at a price of $3.60 per Unit.

Each Unit shall be comprised of one common share of the Company (a “Common Share“) and one-half of one Common Share purchase warrant of the Company (each whole warrant, a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one additional Common Share at an exercise price of $4.50 at any time up to 24 months from Closing (as defined herein).

Provided that if, at any time prior to the expiry date of the Warrants, the volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the “Exchange”), or other principal exchange on which the Common Shares are listed, is greater than $6.75 for 20 consecutive trading days, the Company may, within 15 days of the occurrence of such event, deliver a notice to the holders of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice (the “Accelerated Exercise Period”). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.

The Company has granted the Underwriter an option (the “Underwriters Option”) to increase the size of the Offering by up to an additional number of Units, and/or the components thereof, that in aggregate would be equal to 15% of the total number of Units to be issued under the Offering, at any time up to 30 days following the closing of the Offering.

The net proceeds from the Offering will be used for working capital and general corporate purposes.

The Units will be offered by way of a short form prospectus to be filed in those provinces of Canada as the Underwriter may designate pursuant to National Instrument 44-101 – Short Form Prospectus Distributions and may be offered in the United States on a private placement basis pursuant to an appropriate exemption from the registration requirements under applicable U.S. law.

The Closing of the Offering is expected to occur on or about October 30, 2020 (the (“Closing”) and is subject to the Company receiving all necessary regulatory approvals, including the approval of the Exchange.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

For Further Information, Please Contact:

Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,

Phone: (514) 937-0002, E-mail: [email protected]

RELATED LINK: http://www.pyrogenesis.com/

Cautionary Note Regarding Forward Looking Information:

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

Innocan Pharma’s $INNO.ca Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium #CBD Facial Serum $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:15 PM on Thursday, October 15th, 2020
Innocan-Blog
  • Completed a cosmetic clinical study on 20 volunteers that presented a 90 – 95facial skin wrinkle reduction after using its SHIR ™ Premium CBD Facial Serum
  • “Achieving these amazing results is due to the combination of active ingredients with a specific amount of CBD, result in a tremendous facial skin improvement. The SHIR Beauty & Science skincare brand combines the benefits of CBD’s most effective ingredients into an innovative formula which is leading to visible fast-acting results…” stated Iris Bincovich, Chief Executive Officer of Innocan.”

Herzliya, Israel and Calgary, Alberta–( October 15, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today that it has completed a cosmetic clinical study on 20 volunteers that presented a 90 – 95facial skin wrinkle reduction after using its SHIR ™ Premium CBD Facial Serum. 

The following are the results of the application of the SHIR – Innocan Pharma Facial Serum with 300 mg of Cannabidiol (“CBD”) after 28 days of using the serum twice a day:

The percentage of the subjectsThe subjects considered after using the SHIR™ Premium Facial Serum for 28 days
90%The skin with less wrinkles
95%With finer expression lines
100%The anti-wrinkles effect is the most appreciated product’s effect
90%A more even skin tone
80%A depigmenting effect
85%The skin was more moisturized
90%Evaluated the product as good to very good

Before and After pictures:



Figure1‏ Subject‏ ID‏ ‏126 eye contour wrinkles‏ ‏3D before‏ picture
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/66022_fe9690d2e4cdc93e_002full.jpg


Figure2‏ Subject‏ ID‏ ‏126 eye contour wrinkles‏ ‏3D after 28 days picture
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/66022_fe9690d2e4cdc93e_003full.jpg

“Achieving these amazing results is due to the combination of active ingredients with a specific amount of CBD, result in a tremendous facial skin improvement. The SHIR Beauty & Science skincare brand combines the benefits of CBD’s most effective ingredients into an innovative formula which is leading to visible fast-acting results. Each ingredient was carefully chosen to provide a synergistic effect, working in harmony with each other. The high satisfaction of the volunteers enrolled at the study may indicate a high potential of the targeted market to welcome SHIR Beauty & Science skincare line of products and accelerate InnoCan market penetration,” stated Iris Bincovich, Chief Executive Officer of Innocan.”

The clinical study was conducted by UPTEC, Science and Technology Park of the University of Porto, Portugal which is an independent lab. The findings of the clinical study were consistent with the main principles of ICH GCP, Helsinki declaration and Portuguese legal requirements.

About Innocan

Innocan Israel, a wholly owned subsidiary of the Company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Else Nutrition $BABY.ca Engages Power Digital to Lead Performance Marketing, Influencer and PR Efforts $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 7:23 AM on Thursday, October 15th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Engaged Power Digital, a leader in digital marketing, as its digital marketing agency of record
  • Nationally recognized for its data-driven approach and cross-channel strategies, Power Digital will support Else Nutrition’s U.S. performance marketing with immediate paid advertising campaigns, influencer programming and public relations initiatives.
  • Else Nutrition’s public relations agency, Covet PR, was recently acquired by Power Digital and will continue to support the brand’s PR and communications efforts.

VANCOUVER, BC / October 15, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company“), is pleased to announce it has engaged Power Digital, a leader in digital marketing, as its digital marketing agency of record. Nationally recognized for its data-driven approach and cross-channel strategies, Power Digital will support Else Nutrition’s U.S. performance marketing with immediate paid advertising campaigns, influencer programming and public relations initiatives. Else Nutrition’s public relations agency, Covet PR, was recently acquired by Power Digital and will continue to support the brand’s PR and communications efforts.

“We’re thrilled to bring on Power Digital as a partner to help grow the Else business,” said Hamutal Yitzhak, CEO and Co-Founder of Else. “Between their laser focus on full-funnel marketing and impressive client roster, including Procter & Gamble, Spanx, Casper, SoulCycle and Uniqlo, we are certain that they are the right choice to help Else scale to the next level and bring complete, plant-based nutrition to customers. Power Digital represents the type of world-class brands that we aspire to,” added Mrs. Yitzhak.

“We can’t wait to further support Else Nutrition’s success with a fully-integrated, 360 marketing approach,” said Sara Brooks, President of Covet Consumer Business Unit. “After working with Else Nutrition on PR for the last five months to support its launch in the U.S. market, we look forward to helping the brand continue to take off and bring plant-based nutrition to consumers nationwide.”

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

About Power Digital

Power Digital is a leading, data-driven performance marketing agency located in San Diego, CA. As a full-service agency, the company offers services including: SEO, Content Marketing, Paid Media, Social Media Marketing, PR, Influencer, Email, Conversion Rate Optimization, Amazon Marketing and Web Development, with an emphasis in helping brands scale revenue and increase profits through customer acquisition and retention programs. Its tech-enabled B2C and B2B marketing campaigns focus on measurability and driving bottom line business results. The Power Digital team’s family mentality and growth mindset culture fosters a strong work ethic, innovation and an ownership mentality from its talented team. For more information, please visit powerdigital.com.

Media Contact:

Covet Consumer Business Unit
Gianna Totaro
[email protected]
P: 1-301-875-6574

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will”, “expect” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that listing on the FSE will create additional liquidity and attract additional investors in the European market. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Else Nutrition Holdings Inc.

REMINDER: Innocan Pharma $INNO.ca to Provide Corporate Update via Livestream Video Today at 10am EST $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 8:25 AM on Wednesday, October 14th, 2020
Innocan-Blog

The company will provide a corporate update to the investment community and shareholders through a YouTube livestream video on today at 10:00am EST.

The update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.

The YouTube livestream video will be available through livestream.innocanpharma.com

Hub On AGORACOM / Read Recent Release…

Innocan Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD

  • Study on mice demonstrated a prolonged release of Cannabidiol into the blood for at least three weeks after one administration
  • Conducted based on Innocan’s licensed CBD loaded liposome platform technology for injectable CBD
  • Conducted on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT
  • Results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration
  • Results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

ImagineAR $IP.ca $IPNFF Announces Sticky Media Joins Reseller Program for Canadian Retail Marketplace $DBO.ca $YDX.ca $SEV.ca $NTAR.ca $HIMX

Posted by AGORACOM-JC at 7:21 AM on Wednesday, October 14th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Announced the signing of a reseller agreement with Sticky Media, a digital and physical sign manufacturer based in Montreal, Canada with over 1500 clients in the last 15 years including Psycho Bunny, Vans , Dominos, and Pajar
  • “With over 1500 clients, Sticky Media is one of the leading signage companies in Canada and well positioned to market AR to their new and existing clientele” stated ImagineAR CEO and Founder Alen Paul Silverrstieen. 

VANCOUVER, BC and ERIE, Pa., Oct. 14, 2020 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality Company that enables businesses to instantly create their own mobile phone AR campaigns, is pleased to announce the signing of a reseller agreement with Sticky Media, a digital and physical sign manufacturer based in Montreal, Canada with over 1500 clients in the last 15 years including Psycho Bunny, Vans , Dominos, and Pajar.

“We consider the offer of this AR technology to be extremely timely and valuable. The current pandemic is forcing marketing teams to be even more creative in the way they engage consumers. ImagineAR reality tools will provide new and creative ways to engage with customers during this difficult time of Social Distancing”, said Vincent Bonanno, Sales Director of Sticky Media.  “We believe that our partnership will address an exciting and new model to help maximize the consumer experience in the retail, food service and media industries.”

“With over 1500 clients, Sticky Media is one of the leading signage companies in Canada and well positioned to market AR to their new and existing clientele” stated ImagineAR CEO and Founder Alen Paul Silverrstieen. 

This press release is available on the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders. 

About Sticky Media

Sticky Media is a leader for all visual media needs. The company’s priority is to offer the highest quality products and services at competitive prices to ensure our customer’s full satisfaction. Services include vehicle wraps, printing, lettering, fixtures, retail, window, pop, signage and more.

Believing that diversity as well as close collaboration with our clients is the key to success; we not only integrate our clients’ marketing strategies using the latest in print and digital technologies but strive to always exceed expectation with high impact “outside of the box” solutions, creative concept development, combined with top quality print technology and services. As ecological moralists, we take a lot of pride in that all mass production is done with strategy and a minimal carbon footprint approach.

Always taking into account the fast paced environments of our clients, we pride ourselves on helping our customers make the impossible, possible by delivering on tight deadlines and helping to find creative solutions to fulfill requests, no matter how intricate.

Our bottom line is respect for our art form and the planet as well as a professional and customized approach to any mandate handed to us. This is what has earned us a reputation as trend setting visual communication providers in North America over the past 15 years, largely with the help of our loyal clients.

Innovative ideas, technology and street credibility identify our signature approach. Our portfolio is the reference. To learn more, visit stickymedia.ca

About ImagineAR

ImagineAR Inc. (IP:CSE) (IPNFF: OTCQB) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies. ImagineAR is available as an SDK to be integrated into existing mobile apps.

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO

(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if Imagine AR Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward-looking information is based on certain key expectations and assumptions made by Imagine AR management. Although Imagine AR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Imagine AR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and Imagine AR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Hong-Kong listed H&H leads a $25.7M investment in ELSE Nutrition $BABY.ca $ABT $TSN $CAG

Posted by AGORACOM-JC at 7:17 AM on Tuesday, October 13th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

The global baby & adult nutrition company increases its strategic capital stake in ELSE to $9.75M via its subsidiary NewH2 Limited

  • NewH2 Limited, a subsidiary of Health and Happiness (H&H) International Holdings Limited, a Hong Kong Stock Exchange listed company (1112.HK) has increased their strategic investment in Else by C$4.0 million pursuant to a non-brokered private placement announced on September 15th.
  • With the completion this financing NewH2 owns 10,678,706 shares of the Company and 3,114,121 warrants, which will represent approximately 11.6% of the Company’s issued and outstanding common shares
  • Else intends to use the proceeds of the offering to market its novel, plant-based baby and toddler nutrition products in North America alongside new product development operations.

VANCOUVER, BC / October 13, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company“), a developer of plant-based alternatives to dairy-based baby nutrition, is announcing today that NewH2 Limited, a subsidiary of Health and Happiness (H&H) International Holdings Limited, a Hong Kong Stock Exchange listed company (1112.HK) has increased their strategic investment in Else by C$4.0 million pursuant to a non-brokered private placement announced on September 15th.

The Company intends to use the proceeds of the offering to market its novel, plant-based baby and toddler nutrition products in North America alongside new product development operations. Furthermore, the investment provides the Company with the ability to accelerate and increase its production and supply capabilities, increase marketing activities and introduce its product(s) in new territories globally.

“We are very excited to continue to expand our relationship with H&H. They have been an immensely valuable partner and we look forward to working with their team in new market regions. We hear regularly from families across the globe who are seeking a non-dairy nutrition alternative for their children and we are fortunate to have a global partner supporting our endeavours for introduction of our products to store shelves in North America and beyond,” said Ms. Hamutal Yitzhak, CEO and Co-Founder of Else.

Pursuant to the private placement the Company issued 2,224,111 (the “Units”) at a price of C$2.25 per Unit. Each Unit consisting of one common share and 0.50 share purchase warrants, with each whole warrant (a “Warrant”) entitling the holder to acquire one additional common share of the Company at an exercise price of C$3.25 per share for a period of thirty months from the closing date. With the completion this financing NewH2 owns 10,678,706 shares of the Company and 3,114,121 warrants, which will represent approximately 11.6% of the Company’s issued and outstanding common shares. The units issued will be subject to a 12 month hold period from date of closing.

The Company also pleased to announce that it has closed its previously announced upsized bought deal public offering, lead by Canaccord Genuity, of units (the “Units“) for ‎aggregate gross proceeds of CAD$20.7 million, including the exercise of the over-allotment option in full (the “Offering“). The Company issued ‎‎9,200,000 Units at a price of CAD$2.25 per Unit, each Unit consisting of one common share of the ‎Company (a “Share“) and one-half of one common share purchase warrant, with each whole warrant (a “Warrant“) ‎entitling the holder to purchase one Share at the price of CAD$3.25 per Share until October 6, 2022. ‎The Company has received approval from the TSX Venture Exchange (“TSXV“) to list the Warrants issued pursuant to the Offering, and the Warrants are posted for trading on the TSXV under the ticker symbol “BABY.WT” effective October 8, 2020.

Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is now available for sale on Else’s e-store at elsenutrition.com, and will soon be available on Amazon.com. Consumers can order single 22 oz cans and 4-packs.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

For more information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director of Else Nutrition
Email: [email protected]
Telephone: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Else Nutrition Holdings

Innocan $INNO.ca Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable #CBD $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 4:11 PM on Friday, October 9th, 2020
Innocan-Blog
  • Study on mice demonstrated a prolonged release of Cannabidiol into the blood for at least three weeks after one administration
  • Conducted based on Innocan’s licensed CBD loaded liposome platform technology for injectable CBD
  • Conducted on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT
  • Results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration
  • Results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

Herzliya, Israel and Calgary, Alberta–(October 9, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today that an animal study on mice, demonstrated a prolonged release of Cannabidiol (“CBD”) into the blood for at least three weeks after one administration. This study was conducted by The Hebrew University of Jerusalem, Israel based on Innocan’s licensed CBD loaded liposome platform technology (“LPT”) for injectable CBD.

The study which was led by Dr. Ahuva Cern, Senior Researcher in the lab of Prof. Berenholz, was conducted in The Hebrew University of Jerusalem laboratories on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT.

These results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration.

These results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

Innocan Israel, a wholly owned subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company (“Yissum“), the commercial arm of The Hebrew University of Jerusalem in respect of the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development is led by Professor Chezy Barenholz, head of the Membrane and Liposome research department at The Hebrew University, which was the inventor of over 55 patent families, two of which underlie Doxil® – an FDA approved drug for breast cancer treatment. This unique technology platform may be implemented for several indications such as epilepsy, pain relief, and different inflammation and central nervous system disorders. A patent was filed on this technology on October 7, 2019.

Professor Chezy Berenholz stated, ” I believe that the results of this animal study, showing the prolonged release of CBD into the blood stream is an extremely important major milestone. This may open a wide range of clinical applications which may allow for the maintenance of a certain level of CBD in the blood for a longer period of time which may also lead to improved patient’s compliance. If successful, this technology may be beneficial for various additional indications.”

Iris Bincovich, Innocan’s CEO, added, “As variety of studies demonstrates the effectiveness of cannabinoids in the treatment of various CNS conditions, this has the potential to address indication such as Epilepsy.”

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholz, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.